Manufacturers report positive data for lenzilumab in COVID-19 case-control study

In a study of 39 patients, lenzilumab (an anti-GMCSF monoclonal antibody) was associated with a reduction in risk of progression to invasive mechanical ventilation and/or death vs a cohort of matched controls given standard of care (8% vs. 41%, p=0.07).


Biospace Inc.